Targeted therapies for MASH show progress, with pegozafermin leading in efficacy for fibrosis regression and disease resolution. New research highlights the effectiveness of targeted therapies for ...
Please provide your email address to receive an email when new articles are posted on . AIM-MASH AI Assist is the first AI drug development tool to be qualified by the FDA. The tool is designed to ...
Longer treatment with an Akero Therapeutics drug in development for the liver disease MASH led to better results, including improvement in fibrosis, the liver scarring that is a hallmark of the ...
"[We] have conducted a large individual participant data meta-analysis and shown that screening strategies using sequential application of simple NITs like FIB-4 or NFS followed by LSM-VCTE achieve ...
Wegovy can now be used in adults with metabolic-associated steatohepatitis (MASH) who have excessive scar tissue in their liver. The FDA has expanded Wegovy use to include adults with ...
HistoIndex, a pioneer in AI-driven digital pathology solutions for chronic liver disease, has announced a strategic partnership with Houston Research Institute (HRI). HRI is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results